Heidelberg Pharma AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
June 24, 2021 at 05:13 am EDT
Share
DGAP Voting Rights Announcement: Heidelberg Pharma AG
Heidelberg Pharma AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
24.06.2021 / 11:12
Dissemination of a Voting Rights Announcement transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
Notification of Major Holdings
1. Details of issuer
Name:
Heidelberg Pharma AG
Street:
Gregor-Mendel-Str. 22
Postal code:
68526
City:
Ladenburg Germany
Legal Entity Identifier (LEI):
391200E09XYBYITR1W32
2. Reason for notification
X
Acquisition/disposal of shares with voting rights
Acquisition/disposal of instruments
Change of breakdown of voting rights
Other reason:
3. Details of person subject to the notification obligation
Natural person (first name, surname): Dietmar Hopp Date of birth: 26 Apr 1940
4. Names of shareholder(s)
holding directly 3% or more voting rights, if different from 3.
dievini Hopp BioTech holding GmbH & Co. KG DH-LT-Investments GmbH
5. Date on which threshold was crossed or reached:
22 Jun 2021
6. Total positions
% of voting rights attached to shares (total of 7.a.)
% of voting rights through instruments (total of 7.b.1 + 7.b.2)
Total of both in % (7.a. + 7.b.)
Total number of voting rights pursuant to Sec. 41 WpHG
New
75.32 %
0.00 %
75.32 %
34173009
Previous notification
69.63 %
0.00 %
69.63 %
/
7. Details on total positions a. Voting rights attached to shares (Sec. 33, 34 WpHG)
ISIN
Absolute
In %
Direct (Sec. 33 WpHG)
Indirect (Sec. 34 WpHG)
Direct (Sec. 33 WpHG)
Indirect (Sec. 34 WpHG)
DE000A11QVV0
171538
25567251
0.50 %
74.82 %
Total
25738789
75.32 %
b.1. Instruments according to Sec. 38 (1) no. 1 WpHG
Type of instrument
Expiration or maturity date
Exercise or conversion period
Voting rights absolute
Voting rights in %
0
0.00 %
Total
0
0.00 %
b.2. Instruments according to Sec. 38 (1) no. 2 WpHG
Type of instrument
Expiration or maturity date
Exercise or conversion period
Cash or physical settlement
Voting rights absolute
Voting rights in %
0
0.00 %
Total
0
0.00 %
8. Information in relation to the person subject to the notification obligation
Person subject to the notification obligation is not controlled nor does it control any other undertaking(s) that directly or indirectly hold(s) an interest in the (underlying) issuer (1.).
X
Full chain of controlled undertakings starting with the ultimate controlling natural person or legal entity:
Name
% of voting rights (if at least 3% or more)
% of voting rights through instruments (if at least 5% or more)
Total of both (if at least 5% or more)
-Herr Dietmar Hopp
%
%
%
-DH-Holding GmbH & Co. KG
%
%
%
-DH-Holding Verwaltungs GmbH
%
%
%
-
%
%
%
-Herr Dietmar Hopp
%
%
%
-Hopp LT Vermögensverwaltungs GmbH
%
%
%
-DH-Capital GmbH & Co. KG
%
%
%
-dievini Hopp BioTech holding GmbH & Co. KG
66.39 %
%
66.39 %
-
%
%
%
-Herr Dietmar Hopp
%
%
%
-DH Verwaltungs GmbH
%
%
%
-DH-Capital GmbH & Co. KG
%
%
%
-dievini Hopp BioTech holding GmbH & Co. KG
66.39 %
%
66.39 %
-
%
%
%
-Herr Dietmar Hopp
%
%
%
-DH-LT-Investments GmbH
5.69 %
%
5.69 %
9. In case of proxy voting according to Sec. 34 para. 3 WpHG
(only in case of attribution of voting rights in accordance with Sec. 34 para. 1 sent. 1 No. 6 WpHG)
Date of general meeting:
Holding total positions after general meeting (6.) after annual general meeting:
Proportion of voting rights
Proportion of instruments
Total of both
%
%
%
10. Other explanatory remarks:
Date
23 Jun 2021
24.06.2021 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de
Heidelberg Pharma AG, formerly Wilex AG, is a Germany-based Company, which is engaged in the biopharmaceuticals sector. The Company focuses on the research and development of therapy treatments for oncology area. It aims at applying toxin Amanitin into cancer therapies using its Antibody Targeted Amanitin Conjugate (ATAC) technology. The Companyâs pipeline includes a number of drug candidates, such as HDP-101, a B-cell maturation antigen ATAC for multiple myeloma; PSMA-ATAC, prostate-specific membrane antigens, and CD19-ATAC, a B-lymphocyte antigen. Through partnerships, the Company develops clinical assets, including MESUPRON, REDECTANE and RENCAREX. It also offers preclinical contract research services.
Heidelberg Pharma AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution